Quality of life assessment and patient acceptability of intermittent versus continuous sex hormone suppression as treatment for locally advanced or metastatic prostatic cancer
Completed
- Conditions
- Cancer: ProstateCancerProstate
- Registration Number
- ISRCTN51203558
- Lead Sponsor
- Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 200
Inclusion Criteria
200 patients recruited from Urological Oncology Clinical who have had six months androgen blockade.
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient acceptance, quality of life and survival/disease progression.
- Secondary Outcome Measures
Name Time Method ot provided at time of registration